Efficacy of Cefcapene Pivoxil for Empirical Therapy of Acute Uncomplicated Cystitis

Seung-Ju Lee; U-Syn Ha; Hyun Woo Kim; Yong-Hyun Cho

doi:10.3947/ic.2008.40.3.162

Journal List > Infect Chemother > v.40(3) > 1075398

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Ha, Kim, and Cho: Efficacy of Cefcapene Pivoxil for Empirical Therapy of Acute Uncomplicated Cystitis

Original Article

Infection and Chemotherapy

Infection and Chemotherapy 2008; 40(3): 162-166.

Published online: 20 June 2008

DOI: https://doi.org/10.3947/ic.2008.40.3.162

Efficacy of Cefcapene Pivoxil for Empirical Therapy of Acute Uncomplicated Cystitis

Seung-Ju Lee, M.D., U-Syn Ha, M.D., Hyun Woo Kim, M.D., Yong-Hyun Cho, M.D.

Department of Urology, College of Medicine, Catholic University, Seoul, Korea.

Correspondence: Yong-Hyun Cho, M.D. Department of Urology, College of Medicine, Catholic University, College of Medicine, The Catholic University of Korea, #62 Yoido-dong, Youngdungpogu, St. Mary's Hospital, Seoul, 150-713, Korea. Tel: +82-2-3779-1024, Fax: +82-2-761-1626, cyh0831@catholic.ac.kr

Received 19 May 2008 Accepted 17 June 2008

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

A high prevalence of fluoroquinolone resistance among uropathogens has been observed in Korea. Since empirical antimicrobial therapy should be guided by the proportion of pathogens resistant to the chosen antibiotic, the limitation of fluoroquinolones as the first empirical choice for acute cystitis is noticed in the clinical setting. The present study was undertaken to determine the susceptibility profiles of urinary isolates to cefcapene pivoxil and assess the clinical efficacy in patients with acute uncomplicated cystitis.

Materials and Methods

The study was a prospective, open label, non-comparative, non-blinded trial. Ninety-two patients with acute, uncomplicated symptomatic cystitis from two hospitals were treated with cefcapene pivoxil 100 mg tid for 5 days and followed up for 2 weeks.

Results

Seventy-seven of the 92 patients were evaluated. Bacteriological eradication of initial pathogens was achieved in 97.4% by 2 weeks after therapy termination. Seventy-four of 77 (96.1%) patients were symptomatically cured or improved after completion of therapy. Drug related adverse experiences were seen in 8 patients. None necessitated cessation of therapy. No significant biochemical or hematological abnormalities occurred.

Conclusion

These results demonstrate the clinical efficacy and safety of empirical 5-day cefcapene pivoxil for acute uncomplicated cystitis.

Keywords: Cefcapene pivoxil, Acute uncomplicated cystitis

Figures and Tables

Table 1

Distribution of Detected Baseline Pathogens for Each Group

CNS, coagulase-negative Staphylococci

Table 2

Susceptibility of Uropathogens Isolated from Female Outpatients with Acute Uncomplicated Cystitis to Various Antimicrobial Agents

TMP/SMX, trimethoprim/sulphamethoxazole

References

1. Sobel JD. Bacterial etiologic agents in the pathogenesis of urinary tract infection. Med Clin North Am. 1991. 75:253–273.

2. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001. 135:41–50.

3. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999. 29:745–758.

4. Kim SW, Lee JY, Park WJ, Cho YH, Yoon MS. Antibiotic Sensitivity to the Causative Organism of Acute Simple Urinary Tract Infection. Korean J Urol. 2000. 41:1117–1124.

5. Lee SJ, Cho YH, Kim BW, Lee JG, Jung SI, Lee SD, Lee SE, Kim ME, Choi YD, Rim JS, Sim BS, Cho IR, Ryu SB, Kim CS, Kim WJ, Lee TY. A Multicenter Study of Antimicrobial Susceptibility of Uropathogens Causing Acute Uncomplicated Cystitis in Woman. Korean J Urol. 2003. 44:697–701.

6. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents. 2008. S1:15–18.

7. Saito A, Hiraga Y, Watanabe A, Saito A, Shimada K, Kobayashi H, Odagiri S, Miki F, Soejima R, Oizumi K, Hara K, Nakashima M. The Japanese Cefcapene Study Group. Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method. J Int Med Res. 2004. 32:590–607.

8. National Committee for Clinical Laboratory Standards. NCCLS document M100-S13. Performance standards for antimicrobial susceptibility testing. 2003. Wayne, PA: NCCLS.

9. Nicolle LE. Epidemiology of urinary tract infection. Infect Med. 2001. 18:153–162.

10. Cockerill FR, Edson RS. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1991. 66:1260–1269.

11. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002. 46:2540–2545.

12. Song HJ, KIM SJ. A Study of Antimicrobial Sensitivity to the Causative Organism of Urinary Tract Infection. Korean J Urol. 2005. 46:68–73.

13. Ha US, Kim ME, Kim CS, Shim BS, Han CH, Lee SD, Cho YH. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents. 2008. 31:S96–S101.

TOOLS

Similar articles